HC Wainwright & Co. Downgrades Chinook Therapeutics to Neutral, Announces $40 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce downgraded Chinook Therapeutics (NASDAQ:KDNY) from Buy to Neutral and announced a $40 price target.
June 13, 2023 | 10:12 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Chinook Therapeutics (NASDAQ:KDNY) was downgraded from Buy to Neutral by HC Wainwright & Co. with a $40 price target.
The downgrade from Buy to Neutral by HC Wainwright & Co. indicates a less optimistic outlook for Chinook Therapeutics. This could lead to a short-term negative impact on the stock price as investors may perceive the downgrade as a sign of reduced growth potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100